CD Antigen Cancer Therapy Market Report

Global and Region CD Antigen Cancer Therapy Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 30, 2022
  • PAGES：231
  • REPORT CODE：GMM909138
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of CD Antigen Cancer Therapy market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of CD Antigen Cancer Therapymarket, defines the market attractiveness level of CD Antigen Cancer Therapy market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of CD Antigen Cancer Therapy industry, describes the types of CD Antigen Cancer Therapy market, the applications of major players and the market size, and deeply analyzes the current situation of the global CD Antigen Cancer Therapy market and the development prospects and opportunities of CD Antigen Cancer Therapy industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global CD Antigen Cancer Therapy market in Chapter 13.

    By Player:

    • UCB

    • Merck

    • GLYCART Biotechnology

    • Genentech

    • Biocad

    • Biogen Idec

    • Genmab

    • MedImmune

    • Hetero Drugs

    • Celltrion

    • Sandoz

    • mAbxience

    • AryoGen Biopharma

    By Type:

    • Monoclonal Antibodies

    • Antibody-Drug-Conjugates

    • Tri-Functional and Bi-Specific T-Cell Engager Antibodies

    • Other

    By End-User:

    • Hospitals

    • Clinics

    • Other

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 CD Antigen Cancer Therapy Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 CD Antigen Cancer Therapy Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 CD Antigen Cancer Therapy Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 CD Antigen Cancer Therapy Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise CD Antigen Cancer Therapy Market Analysis and Outlook to 2022

    • 7.1 Global CD Antigen Cancer Therapy Consumption (2017-2022)

    • 7.2 United States CD Antigen Cancer Therapy Consumption (2017-2022)

    • 7.3 Europe CD Antigen Cancer Therapy Consumption (2017-2022)

    • 7.4 China CD Antigen Cancer Therapy Consumption (2017-2022)

    • 7.5 Japan CD Antigen Cancer Therapy Consumption (2017-2022)

    • 7.6 India CD Antigen Cancer Therapy Consumption (2017-2022)

    • 7.7 South Korea CD Antigen Cancer Therapy Consumption (2017-2022)

    8 Region and Country-wise CD Antigen Cancer Therapy Market Analysis and Outlook to 2028

    • 8.1 Global CD Antigen Cancer Therapy Consumption Forecast (2022-2028)

    • 8.2 United States CD Antigen Cancer Therapy Consumption Forecast (2022-2028)

    • 8.3 Europe CD Antigen Cancer Therapy Consumption Forecast (2022-2028)

    • 8.4 China CD Antigen Cancer Therapy Consumption Forecast (2022-2028)

    • 8.5 Japan CD Antigen Cancer Therapy Consumption Forecast (2022-2028)

    • 8.6 India CD Antigen Cancer Therapy Consumption Forecast (2022-2028)

    • 8.7 South Korea CD Antigen Cancer Therapy Consumption Forecast (2022-2028)

    9 Global CD Antigen Cancer Therapy Market Outlook by Types and Applications to 2022

    • 9.1 Global CD Antigen Cancer Therapy Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Antibody-Drug-Conjugates Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Tri-Functional and Bi-Specific T-Cell Engager Antibodies Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Other Consumption and Growth Rate (2017-2022)

    • 9.2 Global CD Antigen Cancer Therapy Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Global CD Antigen Cancer Therapy Market Outlook by Types and Applications to 2028

    • 10.1 Global CD Antigen Cancer Therapy Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Antibody-Drug-Conjugates Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Tri-Functional and Bi-Specific T-Cell Engager Antibodies Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Other Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global CD Antigen Cancer Therapy Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    11 Global CD Antigen Cancer Therapy Import and Export Analysis (Top 5 Countries)

    • 11.1 Global CD Antigen Cancer Therapy Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global CD Antigen Cancer Therapy Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 CD Antigen Cancer Therapy Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global CD Antigen Cancer Therapy Market Competitive Analysis

    • 14.1 UCB

      • 14.1.1 UCB Company Details

      • 14.1.2 UCB CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 UCB CD Antigen Cancer Therapy Product and Service

    • 14.2 Merck

      • 14.2.1 Merck Company Details

      • 14.2.2 Merck CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Merck CD Antigen Cancer Therapy Product and Service

    • 14.3 GLYCART Biotechnology

      • 14.3.1 GLYCART Biotechnology Company Details

      • 14.3.2 GLYCART Biotechnology CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 GLYCART Biotechnology CD Antigen Cancer Therapy Product and Service

    • 14.4 Genentech

      • 14.4.1 Genentech Company Details

      • 14.4.2 Genentech CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Genentech CD Antigen Cancer Therapy Product and Service

    • 14.5 Biocad

      • 14.5.1 Biocad Company Details

      • 14.5.2 Biocad CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Biocad CD Antigen Cancer Therapy Product and Service

    • 14.6 Biogen Idec

      • 14.6.1 Biogen Idec Company Details

      • 14.6.2 Biogen Idec CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Biogen Idec CD Antigen Cancer Therapy Product and Service

    • 14.7 Genmab

      • 14.7.1 Genmab Company Details

      • 14.7.2 Genmab CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Genmab CD Antigen Cancer Therapy Product and Service

    • 14.8 MedImmune

      • 14.8.1 MedImmune Company Details

      • 14.8.2 MedImmune CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 MedImmune CD Antigen Cancer Therapy Product and Service

    • 14.9 Hetero Drugs

      • 14.9.1 Hetero Drugs Company Details

      • 14.9.2 Hetero Drugs CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Hetero Drugs CD Antigen Cancer Therapy Product and Service

    • 14.10 Celltrion

      • 14.10.1 Celltrion Company Details

      • 14.10.2 Celltrion CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Celltrion CD Antigen Cancer Therapy Product and Service

    • 14.11 Sandoz

      • 14.11.1 Sandoz Company Details

      • 14.11.2 Sandoz CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Sandoz CD Antigen Cancer Therapy Product and Service

    • 14.12 mAbxience

      • 14.12.1 mAbxience Company Details

      • 14.12.2 mAbxience CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 mAbxience CD Antigen Cancer Therapy Product and Service

    • 14.13 AryoGen Biopharma

      • 14.13.1 AryoGen Biopharma Company Details

      • 14.13.2 AryoGen Biopharma CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 AryoGen Biopharma CD Antigen Cancer Therapy Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of CD Antigen Cancer Therapy

    • Figure CD Antigen Cancer Therapy Picture

    • Table Global CD Antigen Cancer Therapy Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global CD Antigen Cancer Therapy Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global CD Antigen Cancer Therapy Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global CD Antigen Cancer Therapy Consumption by Country (2017-2022)

    • Figure United States CD Antigen Cancer Therapy Consumption and Growth Rate (2017-2022)

    • Table Europe CD Antigen Cancer Therapy Consumption and Growth Rate (2017-2022)

    • Figure China CD Antigen Cancer Therapy Consumption and Growth Rate (2017-2022)

    • Figure Japan CD Antigen Cancer Therapy Consumption and Growth Rate (2017-2022)

    • Figure India CD Antigen Cancer Therapy Consumption and Growth Rate (2017-2022)

    • Figure South Korea CD Antigen Cancer Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global CD Antigen Cancer Therapy Consumption Forecast by Country (2022-2028)

    • Figure United States CD Antigen Cancer Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe CD Antigen Cancer Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure China CD Antigen Cancer Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan CD Antigen Cancer Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure India CD Antigen Cancer Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea CD Antigen Cancer Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Global Antibody-Drug-Conjugates Consumption and Growth Rate (2017-2022)

    • Figure Global Tri-Functional and Bi-Specific T-Cell Engager Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Antibody-Drug-Conjugates Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tri-Functional and Bi-Specific T-Cell Engager Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Table Global CD Antigen Cancer Therapy Import by Region (Top 5 Countries) (2017-2028)

    • Table Global CD Antigen Cancer Therapy Export by Region (Top 5 Countries) (2017-2028)

    • Table UCB (Foundation Year, Company Profile and etc.)

    • Table UCB CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table UCB CD Antigen Cancer Therapy Product and Service

    • Table Merck (Foundation Year, Company Profile and etc.)

    • Table Merck CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck CD Antigen Cancer Therapy Product and Service

    • Table GLYCART Biotechnology (Foundation Year, Company Profile and etc.)

    • Table GLYCART Biotechnology CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table GLYCART Biotechnology CD Antigen Cancer Therapy Product and Service

    • Table Genentech (Foundation Year, Company Profile and etc.)

    • Table Genentech CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genentech CD Antigen Cancer Therapy Product and Service

    • Table Biocad (Foundation Year, Company Profile and etc.)

    • Table Biocad CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biocad CD Antigen Cancer Therapy Product and Service

    • Table Biogen Idec (Foundation Year, Company Profile and etc.)

    • Table Biogen Idec CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biogen Idec CD Antigen Cancer Therapy Product and Service

    • Table Genmab (Foundation Year, Company Profile and etc.)

    • Table Genmab CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Genmab CD Antigen Cancer Therapy Product and Service

    • Table MedImmune (Foundation Year, Company Profile and etc.)

    • Table MedImmune CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table MedImmune CD Antigen Cancer Therapy Product and Service

    • Table Hetero Drugs (Foundation Year, Company Profile and etc.)

    • Table Hetero Drugs CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hetero Drugs CD Antigen Cancer Therapy Product and Service

    • Table Celltrion (Foundation Year, Company Profile and etc.)

    • Table Celltrion CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celltrion CD Antigen Cancer Therapy Product and Service

    • Table Sandoz (Foundation Year, Company Profile and etc.)

    • Table Sandoz CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sandoz CD Antigen Cancer Therapy Product and Service

    • Table mAbxience (Foundation Year, Company Profile and etc.)

    • Table mAbxience CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table mAbxience CD Antigen Cancer Therapy Product and Service

    • Table AryoGen Biopharma (Foundation Year, Company Profile and etc.)

    • Table AryoGen Biopharma CD Antigen Cancer Therapy Sales, Price, Value and Gross Profit (2017-2022)

    • Table AryoGen Biopharma CD Antigen Cancer Therapy Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US